| Document Type
|
:
|
BL
|
| Record Number
|
:
|
1021757
|
| Doc. No
|
:
|
b776127
|
| Title & Author
|
:
|
Protein tyrosine kinases : : from inhibitors to useful drugs /\ edited by Doriano Fabbro and Frank McCormick.
|
| Publication Statement
|
:
|
Totowa, N.J. :: Humana Press,, ©2006.
|
| Series Statement
|
:
|
Cancer drug discovery and development
|
| Page. NO
|
:
|
1 online resource (xiii, 290 pages) :: illustrations (some color)
|
| ISBN
|
:
|
158829384X
|
|
|
:
|
: 1592599621
|
|
|
:
|
: 9781588293848
|
|
|
:
|
: 9781592599622
|
|
|
:
|
158829384X
|
| Bibliographies/Indexes
|
:
|
Includes bibliographical references and index.
|
| Contents
|
:
|
JAK kinases in leukemias/lymphomas and multiple myeloma / Renate Burger, Martin Gramatzki -- Glivec (Gleevec, Imatinib, STI571) : a targeted therapy for CML / Elisabeth Buchdunger, Renaud Capedeville -- Platelet-derived growth factor : normal function, role in disease, and applications of PDGF antagonists / Tobias Sjoblom [and others] -- Structural biology of protein tyrosine kinases / Sandra W. Cowan-Jacob [and others] -- Testing of signal transduction inhibitors in animal models of cancer / Terence O'Reilly, Robert Cozens -- Phosphoproteomics in drug discovery and development / Michel F. Moran.
|
|
|
:
|
Protein tyrosine kinases as targets for cancer and other indications / Mark Pearson, Carlos Garcia-Echeverria, Doriano Fabbro -- Inhibitors of signaling interfaces : targeting Src homology 2 domains in drug discovery / Carlos Garcia-Echeverria -- PI 3-kinase inhibition : a target for therapeutic intervention / Peter M. Finan, Stephen G. Ward -- Src as a target for pharmaceutical intervention : potential and limitations / Mira Susa [and others] -- Activated FLT3 receptor tyrosine kinase as a therapeutic target in leukemia / Blanca Scheijen, James D. Griffin.
|
| Abstract
|
:
|
In this title, leading researchers, from the Novartis group that pioneered Gleevec/Gliveca and around the world, comprehensively survey the state of the art in the drug discovery processes (bio- and chemoinformatics, structural biology, profiling, generation of resistance, etc.) aimed at generating PTK inhibitors for the treatment of various diseases, including cancer. Highlights include a discussion of the rationale and the progress made towards generating 'selective' low molecular-weight kinase inhibitors; an analysis of the normal function, role in disease, and application of platelet-deriv.
|
| Subject
|
:
|
Cancer-- Chemotherapy.
|
| Subject
|
:
|
Protein-tyrosine kinase-- Inhibitors-- Therapeutic use.
|
| Subject
|
:
|
Biomédecine.
|
| Subject
|
:
|
Cancer-- Chemotherapy.
|
| Subject
|
:
|
HEALTH FITNESS-- Diseases-- Cancer.
|
| Subject
|
:
|
MEDICAL-- Oncology.
|
| Subject
|
:
|
Sciences de la vie.
|
| Subject
|
:
|
Cancer-- Chemotherapy.
|
| Subject
|
:
|
Lymphocyte Specific Protein Tyrosine Kinase p56 (lck)-- physiology.
|
| Subject
|
:
|
Neoplasms-- drug therapy.
|
| Subject
|
:
|
Protein-tyrosine kinase-- Inhibitors-- Therapeutic use.
|
| Subject
|
:
|
Protein-Tyrosine Kinase-- physiology.
|
| Subject
|
:
|
src-Family Kinases-- physiology.
|
| Subject
|
:
|
Protein-Tyrosine Kinases-- pharmacology.
|
| Subject
|
:
|
Protein-Tyrosine Kinases-- therapeutic use.
|
| Subject
|
:
|
Antineoplastic Agents-- pharmacology.
|
| Subject
|
:
|
Drug Design.
|
| Subject
|
:
|
Neoplasms-- drug therapy.
|
| Dewey Classification
|
:
|
616.99/4061
|
| LC Classification
|
:
|
RC271.P76P76 2006
|
| NLM classification
|
:
|
2006 G-948
|
|
|
:
|
QZ 267P9675 2006
|
|
|
:
|
R730. 53clc
|
| Added Entry
|
:
|
Fabbro, D.
|
|
|
:
|
McCormick, Frank,1950-
|